欧洲骨关节浸润关节内注射市场规模和预测（2021-2031 年）、趋势和增长机会分析范围：按类型 [1 型胶原蛋白（聚合、水解和去端肽胶原）和透明质酸]、最终用户（医院、骨科诊所等）和国家/地区划分

Historic Data: 2021-2022   |   Base Year: 2023   |   Forecast Period: 2024-2031

No. of Pages: 90    |    Report Code: BMIRE00030877    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Europe Intra-Articular Injection for Osteoarticular Infiltrations Market
Free Sample Buy Now
欧洲骨关节浸润关节内注射市场规模预计将从 2023 年的 9743 万美元增长到 2031 年的 1.5708 亿美元；预计 2023-2031 年期间的复合年增长率为 6.2%。

骨关节炎关节内注射是一种将药物直接注射到受骨关节炎影响的关节中的医疗程序。这种方法旨在减轻疼痛和改善关节功能。医疗保健专业人员和患者对这些注射的好处的认识不断提高，再加上对医疗保健基础设施和创新的投资不断增加，正在促进更多人获得这些治疗。骨关节炎患病率的不断上升和注射技术的进步是促使欧洲骨关节浸润关节内注射市场规模扩大的值得注意的因素。然而，与关节内注射相关的副作用阻碍了欧洲骨关节浸润关节内注射市场的增长。

关节内注射是治疗骨关节浸润的创新和新兴领域之一。制造商参与各种临床试验，以确保创新药物的安全性、有效性和可靠性。例如，2024 年 5 月，瑞典公司 Synartro 启动了一项 373 万美元至 736 万美元的融资，以对骨关节炎候选药物 SYN321 进行临床研究。该公司正处于获得 278 万美元欧盟拨款的最后阶段。此外，2023 年 4 月，该公司获得瑞典医疗产品管理局和瑞典伦理审查局的批准，开始对研究药物候选药物 SYN321 进行 1/2a 期首次人体临床研究。该地区的其他市场参与者也在进行关节内注射的临床试验，这可以促进创新产品的开发。例如，2022 年 8 月，德国公司 Grünenthal 在其树脂毒素 (RTX) 全球临床 III 期计划中招募了第一位患者。Grünenthal 在欧洲、美国、拉丁美洲、南非和日本的约 200 个地点进行了三项试验，以研究成人关节内注射 RTX 的安全性和有效性。试验中观察到的结果主要集中在从基线到 52 周，西安大略和麦克马斯特大学 (WOMAC) 骨关节炎指数中的身体功能和疼痛评分的改善。完成后，III 期计划旨在为 RTX 在欧洲、美国和日本提供营销批准。该公司打算在 2024 年提交新药申请，表明 RTX 可能在 2025 年进入市场。因此，临床试验数量的增加预计将促进该地区创新产品的开发，这反过来将有助于未来几年欧洲关节内注射骨关节浸润市场的增长。

基于类型的见解

根据类型，欧洲骨关节浸润关节内注射市场细分为 1 型胶原蛋白和透明质酸。 透明质酸细分市场在 2023 年占据欧洲骨关节浸润关节内注射市场的最大份额 透明质酸注射用于治疗对其他治疗方案没有反应的患者的膝盖疼痛。 透明质酸注射疗法的最新进展显着扩展了增长轨迹。 预计对开发和向市场推出新产品的强烈关注将支持该细分市场的增长，从而促进市场增长。

疾病控制和预防中心、世界卫生组织和国家生物技术信息中心是编制欧洲骨关节浸润关节内注射市场报告时参考的主要和次要来源。

Europe Intra-Articular Injection for Osteoarticular Infiltrations Strategic Insights

Strategic insights for Europe Intra-Articular Injection for Osteoarticular Infiltrations involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/europe-intra-articular-injection-for-osteoarticular-infiltrations-market-strategic-framework.webp
Get more information on this report

Europe Intra-Articular Injection for Osteoarticular Infiltrations Report Scope

Report Attribute Details
Market size in 2023 US$ 97.43 Million
Market Size by 2031 US$ 157.08 Million
Global CAGR (2023 - 2031) 6.2%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By 类型
  • 1 型胶原蛋白
  • 透明质酸
By 最终用户
  • 医院
  • 骨科诊所
Regions and Countries Covered 欧洲
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 意大利
  • 欧洲其他地区
Market leaders and key company profiles
  • Bioventus Inc.
  • SEIKAGAKU CORPORATION
  • Maxigen Biotech Inc.
  • stem Medical Inc.
  • Sanofi SA
  • Ferring Pharmaceuticals
  • Fidia Pharma USA Inc.
  • Biotech Healthcare Group
  • Bioteck S.p.A.
  • I+MED.
    		•
    Get more information on this report

    Europe Intra-Articular Injection for Osteoarticular Infiltrations Regional Insights

    The regional scope of Europe Intra-Articular Injection for Osteoarticular Infiltrations refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/europe-intra-articular-injection-for-osteoarticular-infiltrations-market-geography.webp
    Get more information on this report

    The List of Companies - Europe Intra-Articular Injection for Osteoarticular Infiltrations Market

    • Bioventus Inc.
    • SEIKAGAKU CORPORATION
    • Maxigen Biotech Inc.
    • ?stem Medical Inc.
    • Sanofi SA
    • Ferring Pharmaceuticals
    • Fidia Pharma USA Inc.
    • Biotech Healthcare Group
    • Bioteck S.p.A.
    • I+MED.
    Frequently Asked Questions
    How big is the Europe Intra-Articular Injection for Osteoarticular Infiltrations Market?

    The Europe Intra-Articular Injection for Osteoarticular Infiltrations Market is valued at US$ 97.43 Million in 2023, it is projected to reach US$ 157.08 Million by 2031.

    What is the CAGR for Europe Intra-Articular Injection for Osteoarticular Infiltrations Market by (2023 - 2031)?

    As per our report Europe Intra-Articular Injection for Osteoarticular Infiltrations Market, the market size is valued at US$ 97.43 Million in 2023, projecting it to reach US$ 157.08 Million by 2031. This translates to a CAGR of approximately 6.2% during the forecast period.

    What segments are covered in this report?

    The Europe Intra-Articular Injection for Osteoarticular Infiltrations Market report typically cover these key segments-

  • 类型 (1 型胶原蛋白, 透明质酸)
  • 最终用户 (医院, 骨科诊所)

    • What is the historic period, base year, and forecast period taken for Europe Intra-Articular Injection for Osteoarticular Infiltrations Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Intra-Articular Injection for Osteoarticular Infiltrations Market report:

  • Historic Period : 2021-2022
  • Base Year : 2023
  • Forecast Period : 2024-2031
    • Who are the major players in Europe Intra-Articular Injection for Osteoarticular Infiltrations Market?

    The Europe Intra-Articular Injection for Osteoarticular Infiltrations Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Bioventus Inc.
  • SEIKAGAKU CORPORATION
  • Maxigen Biotech Inc.
  • stem Medical Inc.
  • Sanofi SA
  • Ferring Pharmaceuticals
  • Fidia Pharma USA Inc.
  • Biotech Healthcare Group
  • Bioteck S.p.A.
  • I+MED.
    • Who should buy this report?

    The Europe Intra-Articular Injection for Osteoarticular Infiltrations Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Europe Intra-Articular Injection for Osteoarticular Infiltrations Market value chain can benefit from the information contained in a comprehensive market report.

    europe-intra-articular-injection-for-osteoarticular-infiltrations-market